Staburo @ AMI Virtual Student Days

Sep 29, 2023
flyer

Are you interested in shaping the future generation of statistics and data science in the pharmaceutical industry? Staburo will be part of the Academia meets industry (AMI) – virtual students’ day.

The AMI event brings together students and representatives of industry and academia. It will take place on 6th of October from 9:00 am – 12:00 pm. Each time slot will be 20 minutes long and for students there will be enough time to get to know the various companies and universities. For more details please refer to the official flyer:

Our core purpose at Staburo is: Excellent data science to improve and save lives. To follow our purpose and to inspire others – a part of our Staburo team will provide insights on Staburo’s core business and expertise, the development of our company as well as interesting opportunities within our company.

At the end of each session there will be plenty of time for networking and discussions.

Many thanks to the organizers of this event – it is always a pleasure to connect with future talents of our industry.

We are already looking forward to seeing you and answering your questions on October 6th.

More Articles

7th Staburo Health Data Science Summit 

7th Staburo Health Data Science Summit 

The 7th Staburo Health Data Science Summit brought together experts from the pharmaceutical and life sciences industries to explore the evolving role of biomarkers and data science in advancing precision medicine.  With contributions from leading organizations,...

read more
Staburo @ ISCB/GMDS Conference 2026

Staburo @ ISCB/GMDS Conference 2026

Staburo Team Selected to Present at ISCB/GMDS Conference 2026 We are pleased to share that Maria Stark, Senior Data Scientist, and the team representing Staburo in the GMDS Biostatistics Competition have been selected to present their work at the upcoming ISCB/GMDS...

read more
Biomarkers at Staburo

Biomarkers at Staburo

In 2024 at Staburo was about building momentum in the area Biomarkers. Deepening our engagement in the PSI Biomarker SIG, strengthening collaborations, and developing the ideas that would later become deliverables. In 2025, we developed and released ShadowVIMP, an R...

read more